We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01229254
First Posted: October 27, 2010
Last Update Posted: September 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Portola Pharmaceuticals
September 9, 2010
October 27, 2010
July 21, 2017
September 18, 2017
September 18, 2017
September 2010
December 2010   (Final data collection date for primary outcome measure)
Steady-state C12 hr on Days 14, 18, and 21 After Weight-based Dosing [ Time Frame: Days 14, 18, and 21 of the PK period ]
Betrixaban PK concentration at 12 hr on Days 14, 18, and 21 in low and high weight groups
Steady-state plasma concentrations in the lower weight and the higher weight participant groups [ Time Frame: Days 14 through 21 ]
The betrixaban steady-state PK is the endpoint of interest. Measurement is an average concentration from 3 timepoints: Days 14, 18 and 21.
Complete list of historical versions of study NCT01229254 on ClinicalTrials.gov Archive Site
Steady-state C12 hr on Days 14, 18, and 21 After Weight and Amiodarone-based Dosing [ Time Frame: Days 14, 18, and 21 of the PK period ]
Betrixaban PK concentration at 12 hr on Days 14, 18, and 21 in amiodarone, low and high weight groups
Steady-state geometric mean plasma concentrations for the 3 combined arms. [ Time Frame: Days 14, 18 and 21 ]
The steady-state geometric mean plasma concentrations will be evaluated for the 3 arms of betrixaban treatment combined.
Not Provided
Not Provided
 
Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter
The primary purpose of this study is to optimize drug exposure in the target population.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Atrial Fibrillation
  • Atrial Flutter
  • Drug: Amiodarone
    Patients on Amiodarone
  • Drug: Betrixaban 60 mg
    Betrixaban 60 mg once a day with food on Day 0 through Day 25
    Other Name: MK-4448
  • Drug: Betrixaban 90 mg
    Betrixaban 90 mg once a day with food on Day 0 through Day 25
    Other Name: MK-4448
  • Drug: Betrixaban 30 mg
    Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
    Other Name: MK-4448
  • Experimental: Amiodarone
    Participants on betrixaban 30 mg and concomitant baseline amiodarone
    Interventions:
    • Drug: Amiodarone
    • Drug: Betrixaban 30 mg
  • Experimental: Betrixaban 60 mg
    Participants with lower weights
    Intervention: Drug: Betrixaban 60 mg
  • Experimental: Betrixaban 90 mg
    Participants with higher weights
    Intervention: Drug: Betrixaban 90 mg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
189
April 2011
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • In the opinion of the investigator, participant requires long term anticoagulation for stroke prevention in atrial flutter (AF).
  • Men and women ≥18 years of age.
  • Participant has current non-valvular atrial fibrillation (NVAF) or AF or electrocardiogram (ECG) or Holter documentation within past 12 months.
  • Participant has an international normalized ratio (INR) ≤ 2.2 at allocation (Visit 2).
  • A participant who is of reproductive potential agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control for the duration of the study. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, condom, vasectomy, and hormonal contraception.
  • Participant understands the study procedures and risks involved with the study, and voluntarily agree to participate by giving written informed consent.

Exclusion Criteria:

General

  • Participant is currently participating in another drug study or has received an investigational drug within 30 days prior to enrollment.
  • Participant is a woman who is pregnant, lactating or of child-bearing potential who refuses to use a medically acceptable form of contraception throughout the study.
  • Participant has a body weight less than 40 kg (88 lbs) or greater than 200 kg (440 lbs).
  • Participant routinely consumes more than 2 alcoholic drinks per day (average >14 alcoholic drinks per week) or greater than 5 drinks within 2 hours on occasion.

Prohibited Medical Conditions

  • Participant has any condition or situation which, in the opinion of the investigator, might pose a risk to the participant or interfere with participation in the study.
  • Conditions associated with an increased risk of bleeding Active bleeding.
  • Conditions other than AF that require chronic anticoagulation.
  • Severe aortic and mitral valvular disease requiring surgical intervention.
  • Previous known history of coagulopathy (e.g.: Factor V Leiden, Protein C Deficiency, Protein S Deficiency, Antiphospholipid Syndrome, etc.).
  • Active infective endocarditis.
  • Participant has history of familial long QT interval (the QT interval is the portion of an electrocardiogram (ECG) between the onset of the Q wave and the end of the T wave, representing the total time for ventricular depolarization and repolarization) syndrome or prolonged Bazett-corrected QT interval (QTcB) (males > 470 msec; females >480 msec) at baseline as measured on a 12-lead ECG.
  • Participant has serious pulmonary, hepatic, metabolic, gastrointestinal, central nervous system (CNS) or psychiatric disease, end-stage disease states, or any other disease that could interfere with the conduct or validity of the study or compromise participant safety.
  • Participant has a history of malignancy ≤ 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer (melanoma, leukemia, lymphoma and myeloproliferative disorders of any duration are excluded).
  • Participant has a history of mental instability, drug/alcohol abuse within the past 5 years, or major psychiatric illness not adequately controlled and stable on pharmacotherapy.
  • Participant has reversible causes of atrial fibrillation (i.e.: cardiac surgery, pulmonary embolism, untreated hyperthyroidism).
  • Participant is to undergo pulmonary vein isolation or surgery for treatment of AF.
  • Participant had a severe, disabling stroke within the previous 6 months, any stroke within the previous 14 days, thromboembolism within previous 30 days or a transient ischemic attack (TIA) within 3 days prior to Visit 1.
  • Participant requires renal replacement therapies (hemo- or peritoneal dialysis).
  • Participant has any of a list of defined laboratory abnormalities.

Prohibited Medications

  • Anti-platelet agents other than aspirin within 10 days prior to Visit 1 (excluding maintenance dose clopidogrel, prasugrel or ticlopidine) or fibrinolytic agents within 30 days prior to Visit 1.
  • Aspirin greater than 162 mg/day.
  • Daily non-steroidal anti-inflammatory drug (NSAID) use.
  • Dronedarone, verapamil or ketoconazole.
  • Vitamin K antagonists (VKA) or other anticoagulants.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT01229254
006-00
No
Not Provided
Not Provided
Portola Pharmaceuticals
Portola Pharmaceuticals
Not Provided
Not Provided
Portola Pharmaceuticals
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP